

For traditional, 10-year Maintenance of Certification (MOC) exam and Longitudinal Knowledge Assessment (LKA*)

ABIM invites diplomates to help develop the Endocrinology, Diabetes, and Metabolism MOC exam blueprint

Based on feedback from physicians that MOC assessments should better reflect what they see in practice, in 2016 the American Board of Internal Medicine (ABIM) invited all certified endocrinologists to provide ratings of the relative frequency and importance of blueprint topics in practice.

This review process, which resulted in a new MOC exam blueprint, will be used on a periodic basis to inform and update all MOC assessments created by ABIM. No matter what form ABIM's assessments ultimately take, they will need to be informed by front-line clinicians sharing their perspective on what is important to know.

A sample of over 300 endocrinologists, similar to the total invited population of endocrinologists in age, gender, geographic region, and time spent in direct patient care, provided the blueprint topic ratings. ABIM used this feedback to update the blueprint for MOC assessments (beginning with the Fall 2016 administration of the traditional, 10-year MOC exam).

To inform how assessment content should be distributed across the major blueprint content categories, ABIM considered the average respondent ratings of topic frequency and importance in each of the content categories. A second source of information was the relative frequency of patient conditions in the content categories, as seen by certified endocrinologists and documented by national health care data (described further under *Content distribution* below).

To determine prioritization of specific assessment content within each major medical content category, ABIM used the respondent ratings of topic frequency and importance to set thresholds for these parameters in the exam assembly process (described further under *Detailed content outline* below).

Purpose of the Endocrinology, Diabetes, and Metabolism MOC Assessments

MOC assessments are designed to evaluate whether a certified endocrinologist has maintained competence and currency in the knowledge and judgment required for practice. The MOC assessments emphasize diagnosis and management of prevalent conditions, particularly in areas where practice has changed in recent years. As a result of the blueprint review by ABIM diplomates, MOC assessments place less emphasis on rare conditions and focus more on situations in which physician intervention can have important consequences for patients. For conditions that are usually managed by other specialists, the focus will be on recognition rather than on management.

Assessment format

The traditional, 10-year MOC exam contains up to 220 single-best-answer multiple-choice questions, of which approximately 50 are new questions that do not count in the examinee's score. Examinees taking the traditional, ten-year MOC exam will have access to an external resource (i.e., UpToDate*) for the entire exam.

The LKA for MOC is a five-year cycle in which physicians answer questions on an ongoing basis and receive feedback on how they're performing along the way. More information on how exams are developed can be found abim.org/about/exam-information/exam-development.aspx.

Most questions describe patient scenarios and ask about the work done (that is, tasks performed) by physicians in the course of practice:

- Diagnosis: making a diagnosis or identifying an underlying condition
- Testing: ordering tests for diagnosis, staging, or follow-up
- Treatment/Care Decisions: recommending treatment or other patient care
- Risk Assessment/Prognosis/Epidemiology: assessing risk, determining prognosis, and applying principles from epidemiologic studies
- Pathophysiology/Basic Science: understanding the pathophysiology of disease and basic science knowledge applicable to patient care

JANUARY 2025

ABIM is committed to working toward health equity and believes that board-certified physicians should have an understanding of health care disparities. Therefore, health equity content that is clinically important to each discipline will be included in assessments, and the use of gender, race, and ethnicity identifiers will be re-evaluated.

Clinical scenarios presented take place in outpatient or inpatient settings as appropriate to a typical Endocrinology, Diabetes, and Metabolism practice. Clinical information presented may include diagnostic imaging studies, continuous glucose monitoring tracings, radiographic studies, or patient photographs.

Tutorials for the traditional, ten-year MOC exam and for LKA, including examples of ABIM exam question format, can be found at abim.org/maintenance-of-certification/examinformation/endocrinology-diabetes-metabolism/examtutorial.aspx.

Content distribution

Listed below are the major medical content categories that define the domain for the Endocrinology, Diabetes, and Metabolism traditional, 10-year MOC exam and LKA. The relative distribution of content is expressed as a percentage of the total assessment. To determine the content distribution, ABIM considered the average respondent ratings of topic frequency and importance. To cross-validate these self-reported ratings, ABIM also considered the relative frequency of conditions seen in Medicare patients by a cohort of certified endocrinologists. Informed by these data, the Endocrinology, Diabetes, and Metabolism Board Approval Committee and Board determined the content category targets shown below.

CONTENT CATEGORY	TARGET %
Adrenal Disorders	8%
Pituitary Disorders	8%
Lipids, Obesity, and Nutrition	13%
Female Reproduction	5%
Male Reproduction	5%
Diabetes Mellitus and Hypoglycemia	31%
Calcium and Bone Disorders	12%
Thyroid Disorders	18%
Total	100%

The Endocrinology, Diabetes, and Metabolism traditional 10-year MOC exam may cover other dimensions of medicine as applicable to the medical content categories, such as adolescent medicine.

How the blueprint ratings are used to assemble the MOC assessment

Blueprint reviewers provided ratings of relative frequency in practice for each of the detailed content topics in the blueprint and provided ratings of the relative importance of the topics for each of the tasks described in *Assessment format* above. In rating importance, reviewers were asked to consider factors such as the following:

- High risk of a significant adverse outcome
- Cost of care and stewardship of resources
- Common errors in diagnosis or management
- · Effect on population health
- · Effect on quality of life
- When failure to intervene by the physician deprives a patient of significant benefit

Frequency and importance were rated on a three-point scale corresponding to low, medium, or high. The median importance ratings are reflected in the *Detailed content outline* below. The Endocrinology, Diabetes, and Metabolism Board Approval Committee and Board, in partnership with the physician community, have set the following parameters for selecting MOC assessment questions according to the blueprint review ratings:

- At least 75% of questions will address high-importance content (indicated in green)
- No more than 25% of questions will address mediumimportance content (indicated in yellow)
- No exam questions will address low-importance content (indicated in red)

Independent of the importance and task ratings, no more than 25% of questions will address low-frequency content (indicated by "LF" following the topic description).

JANUARY 2025

The content selection priorities below are applicable beginning with the Fall 2016 traditional, 10-year MOC exam and are subject to change in response to future blueprint review.

Note: The same topic may appear in more than one medical content category.

Detailed content outline for the Endocrinology, Diabetes, and Metabolism traditional, 10-year MOC exam and LKA


⊘ .	- High Importance:
_	will address topics

At least 75% of questions s and tasks with this designation.

/ – **Medium Importance**: No more than 25% of questions will address topics and tasks with this designation.


X – **Low Importance**: <u>No</u> questions will address topics and tasks with this designation.


ADRENAL DISORDERS (8% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
GLUCOCORTICOIDS (3.5% of exam)						
Cushing syndrome		\bigcirc	\bigcirc	⊘	⊘	⊘
Management of glucocorticoid therapy		Not App	olicable	⊘	⊘	⊘
Adrenal insufficiency		\bigcirc	\bigcirc	\bigcirc	\bigcirc	⊘
MINERALOCORTICOIDS (2% of exam)						
Hyperaldosteronism		\bigcirc	\bigcirc	⊘	⊘	⊘
Hypoaldosteronism	LF	⊘	⊘	⊘	Ø	⊘
CONGENITAL ADRENAL HYPERPLAS	A (<2	% of exam)				
Congenital adrenal hyperplasia	LF	⊘	⊘	⊘	⊘	⊘
ADRENAL INCIDENTALOMA (<2% of e	xam)					
Adrenal incidentaloma		\bigcirc	\bigcirc	⊘	⊘	⊘
PHEOCHROMOCYTOMA AND PARAG	ANGL	IOMA (<2% of exa	am)			
Pheochromocytoma and paraganglioma	LF	\bigcirc	\bigcirc	⊘	⊘	⊘
ADRENAL CANCER (<2% of exam)						
Adrenal cancer	LF	\checkmark	⊘	⊘	⊘	⊘




Low Importance: No questions will address topics and tasks with this designation.

PITUITARY DISORDERS (8% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
PROLACTIN (<2% of exam)						
Hyperprolactinemia		⊘	⊘	⊘	⊘	⊘
Prolactinomas		\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Normoprolactinemic galactorrhea					⊘	⊘
GROWTH HORMONE (<2% of exam)						
Acromegaly	LF	⊘	\bigcirc	⊘	⊘	⊘
Growth hormone deficiency	LF	⊘	⊘	⊘	⊘	⊘
THYROID-STIMULATING HORMONI	E (TSH) (<2% of exam)				
TSH-secreting adenoma	LF	⊘	⊘	⊘	⊘	⊘
Hyperplasia secondary to longstanding primary hypothyroidism	LF	⊘	⊘		⊘	⊘
TSH deficiency	LF	\bigcirc	\bigcirc	⊘	⊘	⊘
GONADOTROPINS (<2% of exam)						
Gonadotroph pituitary tumors	LF	⊘	⊘	⊘	⊘	⊘
Hypogonadotropic hypogonadism		⊘	\bigcirc	⊘	⊘	⊘
NONSECRETING PITUITARY TUMO	RS (<2%	of exam)				
Nonsecreting pituitary tumors		\bigcirc	\bigcirc	⊘	⊘	⊘
ADRENOCORTICOTROPIC HORMO	NE (AC	Γ H) (<2% of exam)				
Cushing disease	LF	\bigcirc	\bigcirc	⊘	\bigcirc	⊘
ACTH deficiency	LF	\bigcirc	\bigcirc	⊘	⊘	Ø
HYPOPITUITARISM (<2% of exam)						
Hypopituitarism		\bigcirc	\bigcirc	⊘	⊘	\bigcirc







PITUITARY DISORDERS continued				Risk Assessment/	
(8% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Prognosis/ Epidemiology	Pathophysiology/ Basic Science
EMPTY SELLA SYNDROME (<2% of exam)					
Empty sella syndrome	\bigcirc	\bigcirc	\bigcirc	⊘	⊘
ANTIDIURETIC HORMONE (ADH) (<2% of exa	am)				
Arginine vasopressin deficiency LF	\bigcirc	\bigcirc	⊘	⊘	⊘
Arginine vasopressin resistant	\bigcirc	\bigcirc	⊘	⊘	⊘
Psychogenic polydipsia	\bigcirc	\bigcirc	\bigcirc	\bigcirc	⊘
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)	\bigcirc	⊘	⊘		⊘
CRANIOPHARYNGIOMA (<2% of exam)					
Craniopharyngioma LF	⊘		⊘	⊘	⊘
PITUITARY INCIDENTALOMA (<2% of exam)					
Pituitary incidentaloma	\bigcirc	\bigcirc	⊘	⊘	⊘
LIPIDS, OBESITY, AND NUTRITION (13% of exam)			Treatment/	Risk Assessment/ Prognosis/	Pathophysiology/
	Diagnosis	Testing	Care Decisions	Epidemiology	Basic Science
HYPERCHOLESTEROLEMIA (<2% of exam)	Diagnosis	Testing			
	Diagnosis	Testing			
HYPERCHOLESTEROLEMIA (<2% of exam)	Diagnosis	Testing			
HYPERCHOLESTEROLEMIA (<2% of exam) Primary disorders	_		Care Decisions	Epidemiology	Basic Science
HYPERCHOLESTEROLEMIA (<2% of exam) Primary disorders Familial hypercholesterolemia	⊘	⊘	Care Decisions	Epidemiology	Basic Science
HYPERCHOLESTEROLEMIA (<2% of exam) Primary disorders Familial hypercholesterolemia Secondary disorders	⊘	⊘	Care Decisions	Epidemiology	Basic Science
HYPERCHOLESTEROLEMIA (<2% of exam) Primary disorders Familial hypercholesterolemia Secondary disorders HYPERTRIGLYCERIDEMIA (2% of exam)	✓✓	✓✓	Care Decisions	Epidemiology	Basic Science
HYPERCHOLESTEROLEMIA (<2% of exam) Primary disorders Familial hypercholesterolemia Secondary disorders HYPERTRIGLYCERIDEMIA (2% of exam) Hypertriglyceridemia	✓✓	✓✓	Care Decisions	Epidemiology	Basic Science
HYPERCHOLESTEROLEMIA (<2% of exam) Primary disorders Familial hypercholesterolemia Secondary disorders HYPERTRIGLYCERIDEMIA (2% of exam) Hypertriglyceridemia ELEVATED TRIGLYCERIDES AND LOW-DEN	SITY LIPOPROTI		Care Decisions Output Outpu	Epidemiology	Basic Science
HYPERCHOLESTEROLEMIA (<2% of exam) Primary disorders Familial hypercholesterolemia Secondary disorders HYPERTRIGLYCERIDEMIA (2% of exam) Hypertriglyceridemia ELEVATED TRIGLYCERIDES AND LOW-DEN Primary disorders	SITY LIPOPROTI	EIN CHOLESTEI	Care Decisions O ROL (3% of exam)	Epidemiology	Basic Science




 Low Importance: No questions will address topics and tasks with this designation.

LIPIDS, OBESITY, AND NUTRITION continued (13% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
TREATMENT OF LIPID DISORDERS (5% of	exam)				
Treatment of lipid disorders	⊘	\bigcirc	⊘	⊘	⊘
OBESITY AND NUTRITION (2.5% of exam)					
Genetic disorders	⊘	\bigcirc	⊘	⊘	⊘
Secondary disorders	⊘	⊘	⊘	⊘	⊘
Comorbidities	⊘	\bigcirc	⊘	⊘	⊘
Treatment of obesity					
Diet	Not App	olicable	⊘	⊘	⊘
Drugs	Not App	olicable	⊘	⊘	⊘
Lifestyle	Not App	olicable	⊘	⊘	⊘
Surgery and endoscopic treatments	⊘	\bigcirc	\bigcirc	\bigcirc	
GENERAL NUTRITION (<2% of exam)					
Vitamin deficiency	⊘	⊘	⊘	⊘	⊘
Enteral nutrition	⊘	⊘	⊘	⊘	⊘
STRATEGIES FOR COUNSELING (<2% of ex	kam)				
Strategies for counseling	⊘	⊘	Ø	Ø	⊘







FEMALE REPRODUCTION (5% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
AMENORRHEA (<2% of exam)						
Primary						
Androgen insensitivity syndrome	LF	⊘		⊘	×	×
Turner syndrome	LF	⊘	⊘	⊘	⊘	⊘
Primary ovarian insufficiency	LF	⊘	⊘	\bigcirc	⊘	⊘
Secondary		\bigcirc	\bigcirc	⊘	⊘	⊘
HYPERANDROGENISM (<2% of example))					
Polycystic ovary syndrome		⊘	\bigcirc	⊘	⊘	⊘
Non-polycystic ovary syndrome		⊘	(⊘	×	×
Nonclassic congenital adrenal hyperplasia	LF		⊘	⊘	⊘	⊘
Abuse of anabolic steroids	LF				×	×
PREMENSTRUAL SYNDROME AND F	PREME	ENSTRUAL DYSPH	ORIC DISORD	ER (<2% of exam)		
Premenstrual syndrome and premenstrual dysphoric disorder	LF	⊘	⊘	⊘	×	×
ENDOCRINE CAUSES OF INFERTILIT	Y (<29	% of exam)				
Endocrine causes of infertility		⊘	⊘	⊘	×	×
HORMONAL CONTRACEPTION (<2%	of exa	ım)				
Hormonal contraception		Not Appl	icable	⊘	⊘	×
PERIMENOPAUSE AND MENOPAUSE	(<2%	of exam)				
Perimenopause and menopause		⊘	⊘	⊘	⊘	⊘
SEXUAL DIFFERENTIATION (<2% of e	exam)					
Gender dysphoria	LF	⊘	⊘	⊘	⊘	×
Female-to-male transition management	LF	Not Applicable	⊘	⊘	⊘	×




Low Importance: No questions will address topics and tasks with this designation.


MALE REPRODUCTION (5% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
HYPOGONADISM (3% of exam)						
Primary hypogonadism		\bigcirc	\bigcirc	⊘	⊘	⊘
Secondary hypogonadism		⊘	\bigcirc	⊘	⊘	⊘
Genetic disorders of androgen production and action	LF	⊘	⊘	⊘	×	\otimes
INFERTILITY (<2% of exam)						
Cryptorchidism	LF	⊘	×	×	×	×
Klinefelter syndrome	LF	⊘	⊘	⊘	⊘	⊘
Cystic fibrosis and cystic fibrosis gene mutations	LF	⊘	×	×	×	×
Drug-induced infertility	LF	⊘			⊘	⊘
Obstructive azoospermia	LF	\bigotimes	\bigotimes	×	×	×
Idiopathic oligozoospermia	LF	\bigotimes	\bigotimes	×	×	×
Y-chromosome microdeletions	LF	×	×	×	×	×
GYNECOMASTIA (<2% of exam)						
Gynecomastia		\bigcirc	\bigcirc	⊘	⊘	⊘
ERECTILE DYSFUNCTION (<2% of ex	(am)			'		
Erectile Dysfunction		⊘	\bigcirc	⊘	⊘	⊘
TESTOSTERONE IN AGING MEN (<2	% of exa	nm)				
Testosterone in aging men		\bigcirc	⊘	⊘	⊘	⊘
ABUSE OF ANDROGENS AND ANAB	OLIC ST	TEROIDS (<2% of	f exam)			
Abuse of androgens and anabolic steroids		⊘	⊘	⊘	⊘	⊘






MALE REPRODUCTION					Risk Assessment/	
continued (5% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Prognosis/ Epidemiology	Pathophysiology/ Basic Science
SEXUAL DIFFERENTIATION (<2% o	f exam)					'
Gender dysphoria	LF	⊘	⊘	⊘	⊘	×
Male-to-female transition management	LF	Not Applicable	⊘	⊘	Ø	×
EJACULATORY DYSFUNCTIONS (<	2% of ex	ram)				
Ejaculatory dysfunctions	LF	\otimes	×	×	×	×
DIABETES MELLITUS AND HYPOGLYCEMIA (31% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
PREDIABETES (2% of exam)						
Prediabetes		⊘	\bigcirc	⊘	⊘	⊘
MONITORING GLYCEMIC CONTRO)L (2% of	exam)				
Monitoring glycemic control		⊘	\bigcirc	⊘	⊘	⊘
TYPE 1 DIABETES MELLITUS (4.5%	of exam	1)				
Ketoacidosis		⊘	\bigcirc	⊘	⊘	⊘
Latent autoimmune diabetes of the adult (LADA)	ie	⊘	\bigcirc	⊘	⊘	⊘
Hyperglycemia		⊘	\bigcirc	⊘	\bigcirc	⊘
Hypoglycemia		⊘	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Pathogenesis		⊘	\bigcirc	\bigcirc	\bigcirc	⊘
TYPE 2 DIABETES MELLITUS (5.5%	of exam	n)				
Hyperosmolar nonketotic state		⊘	\bigcirc	⊘	⊘	⊘
Hyperglycemia		⊘	\bigcirc	⊘	⊘	⊘
Hypoglycemia		⊘	\bigcirc	⊘	⊘	⊘
Pathogenesis		⊘	\bigcirc	⊘	\bigcirc	✓
ADDITIONAL TYPES OF DIABETES	(<2% of	exam)				
Additional types of diabetes		⊘	⊘	⊘	⊘	✓






DIABETES MELLITUS AND HYPOGLYCEMIA continued (31% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
RECOGNITION AND MANAGEMENT OF	ASSOCIATED COND	ITIONS (2% of e	exam)		
Hypertension	⊘	\bigcirc	⊘	⊘	⊘
Dyslipidemia	⊘	\bigcirc	⊘	⊘	⊘
Obesity	⊘	\bigcirc	⊘	⊘	⊘
Sleep apnea	⊘	\bigcirc	⊘	⊘	⊘
Fatty liver	⊘	\bigcirc	⊘	⊘	⊘
Thyroid disease	⊘	\bigcirc	⊘	⊘	⊘
RECOGNITION AND MANAGEMENT OF	ASSOCIATED COND	ITIONS continue	ed (2% of exam)		
Polycystic ovary syndrome	⊘	\bigcirc	⊘	\bigcirc	✓
Eating disorders	LF 🗸	⊘	⊘	⊘	⊘
PREGNANCY (<2% of exam)					
Gestational diabetes	⊘	\bigcirc	⊘	⊘	⊘
Pre-gestational diabetes	⊘	⊘	⊘	⊘	⊘
DIABETES MELLITUS COMPLICATIONS	(5% of exam)				
Microvascular	⊘	⊘	⊘	\bigcirc	✓
Macular edema	⊘	⊘	⊘	⊘	✓
Mononeuropathies	LF 🗸	⊘	⊘	⊘	×
Macrovascular	⊘	⊘	⊘	⊘	✓
Diabetic foot	⊘	⊘	⊘	⊘	✓
Skin disorders	⊘	⊘	⊘	⊘	⊘




Low Importance: No questions will address topics and tasks with this designation.


DIABETES MELLITUS AND HYPOGLYCEMIA						
continued (31% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
PANCREAS TRANSPLANTATION (<2	% of exa	ım)				1
Pancreas transplantation	LF	⊘	⊘	⊘	⊘	⊘
HYPOGLYCEMIA INDEPENDENT OF	DIABET	TES (2% of exam)				
Insulinoma	LF	\bigcirc	\bigcirc	\bigcirc	⊘	⊘
Noninsulinoma	LF	\bigcirc	\bigcirc	Ø	⊘	Ø
INPATIENT DIABETES MANAGEMEN	IT (<2%	of exam)				
Inpatient diabetes management		\bigcirc	\bigcirc	⊘	\bigcirc	⊘
CALCIUM AND BONE DISORDEI (12% of exam)	RS	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
HYPERCALCEMIA (3% of exam)						
Parathyroid hormone-mediated						
Primary hyperparathyroidism		\bigcirc	\bigcirc	\bigcirc	\bigcirc	()
Non-parathyroid hormone- mediated		\bigcirc	\bigcirc	\bigcirc	⊘	⊘
HYPOCALCEMIA (3% of exam)						
Hypoparathyroidism		\bigcirc	\bigcirc	⊘	⊘	⊘
Parathyroid hormone (PTH) resistance	LF	⊘	⊘	⊘	×	
Hypomagnesemia	LF	✓	⊘	✓	⊘	⊘
Hyperphosphatemia	LF	✓		✓	✓	⊘
Hypocalcemia (general)		\bigcirc	\bigcirc	\bigcirc	✓	⊘
OSTEOPOROSIS (4% of exam)						
In female		\bigcirc	\bigcirc	⊘	⊘	⊘
In male		\bigcirc	\bigcirc	⊘	⊘	⊘
Post-transplant and glucocorticoid-induced		⊘	⊘	⊘	⊘	⊘
Renal, hepatic, and gastrointestina disease related	I			⊘		




Low Importance: No questions will address topics and tasks with this designation.

CALCIUM AND BONE DISORDE continued (12% of exam)	ERS	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
PAGET DISEASE OF BONE (<2% of	exam)					
Paget disease of bone	LF	\bigcirc	\bigcirc		/	
HYPOVITAMINOSIS D (<2% of exam	n)					
Dietary deficiency		⊘	⊘	⊘	/	⊘
Limited sun exposure		✓	⊘	⊘	✓	⊘
Malabsorption		⊘	⊘	⊘	⊘	⊘
Liver failure	LF	⊘	⊘	⊘	×	×
Renal insufficiency		⊘	⊘	⊘	⊘	⊘
Vitamin D dependent rickets type I and II	LF	⊘	⊘	⊘	×	⊘
Vitamin D resistant rickets	LF	⊘	(⊘	×	⊘
Drug-induced	LF	⊘	(⊘	×	⊘
Bone disease		⊘	⊘	⊘	⊘	⊘
Nonskeletal disorders	LF	⊘		⊘	×	\otimes
OSTEOMALACIA AND RICKETS (<2	2% of exam	n)				
Chronic hypophosphatemia	LF	⊘	⊘	⊘	×	⊘
Inhibitors of mineralization	LF	⊘	⊘	✓	×	×
RENAL OSTEODYSTROPHY (<2% o	of exam)			,		
Renal osteodystrophy		⊘	⊘	Ø	⊘	⊘
NEPHROLITHIASIS (<2% of exam)		,				
Nephrolithiasis		⊘	⊘		⊘	⊘
OSTEOGENESIS IMPERFECTA ANI	D BONE D	YSPLASIAS (<2%	% of exam)			
Osteogenesis imperfecta and bor dysplasias	ne LF	⊘	⊘	⊘	×	×
FIBROUS DYSPLASIA AND OTHER	DYSPLAS	STIC SYNDROMI	ES (<2% of exan	n)		
Fibrous dysplasia and other dysplastic syndromes	LF	×	×	\otimes	×	×





CALCIUM AND BONE DISORDERS continued				Treatment/	Risk Assessment/ Prognosis/	Pathophysiology/
(12% of exam)		Diagnosis	Testing	Care Decisions	Epidemiology	Basic Science
CALCIPHYLAXIS (<2% of exam)						
Calciphylaxis	LF	⊘	⊘	⊘	×	×
HYPOPHOSPHATEMIA (<2% of exam)						
Renal losses	LF	⊘	⊘	⊘	×	×
Gastrointestinal malabsorption	LF	⊘	⊘	⊘	×	×
Internal redistribution	LF	×	×	×	×	×
RARE BONE DISEASES (<2% of exam)						
Hypophosphatasia	LF	/ *	/ *	⊘ *	*	X *
Fibrodysplasia ossificans progressiva	LF	/ *	⊘ *	*	*	*
Osteopetrosis	LF	/ *	⊘ *	✓ *	*	*
THYROID DISORDERS (18% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
HYPERTHYROIDISM (4% of exam)						
Graves disease		\bigcirc	\bigcirc	⊘	⊘	⊘
Toxic adenoma and multinodular goiter		\bigcirc	⊘	⊘	⊘	⊘
Inappropriate thyroid-stimulating hormone syndromes		\bigcirc	\bigcirc	⊘		⊘
Thyrotoxicosis with low radioactive id	odine	uptake				
Thyroiditis		⊘	\bigcirc	⊘	⊘	⊘
Factitious, accidental, and iatrogenic thyrotoxicosis	LF	\bigcirc	\bigcirc	⊘	⊘	⊘
lodine-induced and other drug-induced	LF	⊘	⊘	⊘	⊘	⊘
Struma ovarii	LF	⊘	⊘	⊘	×	×
Complicated thyrotoxicosis	LF	\bigcirc	\bigcirc	\bigcirc	⊘	⊘
Subclinical hyperthyroidism		\bigcirc	\bigcirc	⊘	⊘	⊘



Low Importance: No questions will address topics and tasks with this designation.

THYROID DISORDERS continued				Treatment/	Risk Assessment/ Prognosis/	Pathophysiology/
(18% of exam)		Diagnosis	Testing	Care Decisions	Epidemiology	Basic Science
HYPOTHYROIDISM (3% of exam)						
Primary		\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Secondary		\bigcirc	\bigcirc	⊘	⊘	⊘
Subclinical hypothyroidism		\bigcirc	\bigcirc	⊘	⊘	⊘
Complicated hypothyroidism	LF	\bigcirc	\bigcirc	⊘	⊘	⊘
TSH resistance	LF	×	\otimes	×	×	×
Therapy		Not App	olicable	⊘	⊘	⊘
NONTOXIC SOLITARY NODULES ANI	O MULT	INODULAR GOIT	ΓER (2.5% of exa	am)		
Nontoxic solitary nodules and multinodular goiter		\bigcirc	\bigcirc	⊘	⊘	⊘
THYROID CANCER (4% of exam)						
Well-differentiated epithelial cancers		\bigcirc	\bigcirc	⊘	⊘	⊘
Hürthle cell cancer	LF	\bigcirc	\bigcirc	⊘	⊘	⊘
Anaplastic cancer	LF	\bigcirc		⊘	⊘	×
Lymphoma	LF	⊘		⊘	⊘	×
Medullary cancer	LF	\bigcirc	\bigcirc	⊘	⊘	⊘
THYROID TEST ABNORMALITIES WI	THOUT	THYROID DISEA	ASE (2.5% of exa	am)		
Euthyroid hypothyroxinemia		\bigcirc	\bigcirc	⊘	⊘	⊘
Euthyroid hyperthyroxinemia	LF	⊘	⊘	⊘	⊘	⊘
Effect of drugs on thyroid function tests		⊘	\bigcirc	⊘	⊘	⊘
Nonthyroidal illness (euthyroid sick syndrome)		⊘	\bigcirc	⊘	⊘	⊘
Thyroid hormone antibodies		\bigcirc	\bigcirc	⊘	⊘	⊘
Antibody interferences with TSH measurement	LF	⊘	⊘	⊘		⊘
THYROID DISEASES IN PREGNANCY	′ (<2% o	f exam)				
Thyroid disease in pregnancy		⊘	\bigcirc	⊘	⊘	\bigcirc